AR072876A1 - Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras. - Google Patents

Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras.

Info

Publication number
AR072876A1
AR072876A1 ARP090102799A ARP090102799A AR072876A1 AR 072876 A1 AR072876 A1 AR 072876A1 AR P090102799 A ARP090102799 A AR P090102799A AR P090102799 A ARP090102799 A AR P090102799A AR 072876 A1 AR072876 A1 AR 072876A1
Authority
AR
Argentina
Prior art keywords
halogen
disorders
lower alkyl
chr
substituted
Prior art date
Application number
ARP090102799A
Other languages
English (en)
Inventor
Guido Galley
Annick Goergler
Zbinden Katrin Groebke
Roger Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072876(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR072876A1 publication Critical patent/AR072876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos de formula 1 en el que R1 es hidrogeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halogeno, alcoxi inferior sustituido por halogeno, halogeno, ciano, nitro, hidroxi, C(O)O-alquilo inferior, S(O)2-alquilo inferior, C(O)OCH2-fenilo, OCH2-fenilo, tetrazol-1-ilo, fenilo opcionalmente sustituido por halogeno, o es feniloxi opcionalmente sustituido por halogeno, o es bencilo opcionalmente sustituido por halogeno o es benciloxi opcionalmente sustituido por halogeno, en el que los sustituyentes para n> 1 pueden ser el mismo o diferente; X es -O-(CH2)2-, -O-CHRö-CH2-.-O-CH2-CHR', -O-CR''2-CH2-, -(CH2)2-CHR', -CHR'-(CH2)2-, -CR''2-(CH2)2-, -CH2-CHR'-CH2-, -CH2-CRö2-CH2-, -CHRö-O-CH2-, -CH2-O-CH2-, -CRö2-O-CH2-, -CF2(CH2)2-, -CRö2-CH2-, -SiRö2-(CH2)2-, -S-(CH2)2-, -S(O)2-(CH2)2-, -(CH2)4-, -CH2-O-(CH2)2-, ,o grupo de formulas 2; para m siendo 0, 1, 2 o 3; R' es alquilo inferior, alcoxi inferior o alquilo inferior sustituido por halogeno; R'' es alquilo inferior o alquilo inferior sustituido por halogeno; R2 es hidrogeno o alquilo inferior; Y es arilo, cicloalquilo o heteroarilo; n es 1,2 o 3; o una sal de adicion ácida farmacéuticamente adecuada. Los compuestos descritos en la presente formula 1 pueden utilizarse para el tratamiento de enfermedades relacionadas con la funcion biologica de los receptores asociados a aminas traza, cuyas enfermedades son la depresion, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atencion por hiperactividad, trastornos relacionados con el estrés, trastornos psicoticos, esquizofrenia, enfermedades neurologicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, migrana, abuso de sustancias y trastornos metabolicos, trastornos alimenticios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo de energía y asimilacion, trastornos y disfuncion de la homeostasis de la temperatura corporal, trastornos del sueno y del ritmo circadiano, y trastornos cardiovasculares.
ARP090102799A 2008-07-24 2009-07-23 Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras. AR072876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161060 2008-07-24

Publications (1)

Publication Number Publication Date
AR072876A1 true AR072876A1 (es) 2010-09-29

Family

ID=41066683

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102799A AR072876A1 (es) 2008-07-24 2009-07-23 Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras.

Country Status (22)

Country Link
US (2) US20100041686A1 (es)
EP (1) EP2321287B1 (es)
JP (1) JP5547187B2 (es)
KR (1) KR101307007B1 (es)
CN (1) CN102083805A (es)
AR (1) AR072876A1 (es)
AU (1) AU2009273324A1 (es)
BR (1) BRPI0916363A2 (es)
CA (1) CA2728480A1 (es)
CL (1) CL2011000137A1 (es)
CO (1) CO6331336A2 (es)
CR (1) CR11843A (es)
EC (1) ECSP11010782A (es)
ES (1) ES2556633T3 (es)
IL (1) IL209423A0 (es)
MA (1) MA32486B1 (es)
MX (1) MX2011000464A (es)
PE (1) PE20110215A1 (es)
RU (1) RU2513086C2 (es)
TW (1) TW201008916A (es)
WO (1) WO2010010014A1 (es)
ZA (1) ZA201008657B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148558A (en) 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
CA2791281A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US8673950B2 (en) * 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
KR102537050B1 (ko) 2016-03-17 2023-05-26 에프. 호프만-라 로슈 아게 Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체
CN109071518A (zh) * 2016-05-04 2018-12-21 普渡制药公司 噁唑啉假二聚体、药物组合物及其用途
WO2017210616A1 (en) * 2016-06-02 2017-12-07 Purdue Pharma L.P. Trace amine associated receptor 1 agonists and partial agonists for pain treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) * 1956-01-17 Nxg hi
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
DE1150180B (de) * 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
US3577428A (en) * 1969-04-14 1971-05-04 Colgate Palmolive Co 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines
BE754820R (fr) * 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
US4311840A (en) * 1980-11-13 1982-01-19 E. R. Squibb & Sons, Inc. 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones
EP0096297B1 (de) * 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
DK302185A (da) * 1984-07-05 1986-01-06 Rolland Sa A 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
EP1073640B1 (en) * 1998-04-23 2005-04-13 Takeda Pharmaceutical Company Limited Naphthalene derivatives, their production and use
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
JP2008514603A (ja) * 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド α２アドレナリン作動剤としての４−（ヘテロアリール−メチルおよび置換ヘテロアリール−メチル）−イミダゾール−２−チオン
JP2009524616A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ疾患のための４−イミダゾール誘導体の使用
BRPI0806940A2 (pt) * 2007-02-02 2014-05-06 Hoffmann La Roche 2-amino-oxazolinas como ligantes taar1 para distúrbios do snc

Also Published As

Publication number Publication date
EP2321287B1 (en) 2015-11-11
ZA201008657B (en) 2011-10-26
RU2513086C2 (ru) 2014-04-20
ES2556633T3 (es) 2016-01-19
MX2011000464A (es) 2011-03-01
MA32486B1 (fr) 2011-07-03
WO2010010014A1 (en) 2010-01-28
KR101307007B1 (ko) 2013-09-11
CR11843A (es) 2011-02-16
RU2011104433A (ru) 2012-08-27
US20120165294A1 (en) 2012-06-28
CA2728480A1 (en) 2010-01-28
JP2011528685A (ja) 2011-11-24
CO6331336A2 (es) 2011-10-20
CL2011000137A1 (es) 2011-07-15
EP2321287A1 (en) 2011-05-18
PE20110215A1 (es) 2011-03-31
US20100041686A1 (en) 2010-02-18
KR20110020936A (ko) 2011-03-03
IL209423A0 (en) 2011-01-31
BRPI0916363A2 (pt) 2018-05-29
TW201008916A (en) 2010-03-01
ECSP11010782A (es) 2011-02-28
CN102083805A (zh) 2011-06-01
AU2009273324A1 (en) 2010-01-28
JP5547187B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
AR072876A1 (es) Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras.
BR112013024312A2 (pt) derivados de amina heterocíclica
AR065128A1 (es) Derivados de 2-aminooxazolinas como ligandos taar1. procesos de obtencion, composiciones farmaceuticas y usos
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
AR088741A1 (es) Derivados de pirazol
AR059206A1 (es) Uso de derivados de 4-imidazol para trastornos del snc
AR086880A1 (es) Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central
ECSP12012098A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
CO6531470A2 (es) Derivados benzamida sustituidos
AR063326A1 (es) Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central
RU2669943C2 (ru) Производные 1,7-нафтиридин-3-карбоксамида, полезные в качестве нейрогенных агентов
AR089691A1 (es) Derivados heterociclicos
AR078958A1 (es) Derivados de oxazolina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por los receptores taar1
AR092537A1 (es) Derivados de pirazol-carboxamida
MX2016013412A (es) Derivados de morfolina-piridina.
AR059182A1 (es) Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos
BR112013010558A2 (pt) derivados de di-hidro-oxazol-2-amina
MX2016012624A (es) Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1).
AR093372A1 (es) Derivados de pirazina
AR063811A1 (es) 4-imidazoles sustituidos
AR067675A1 (es) 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc.
AR078556A1 (es) Monohidrato de pardoprunox
TH108796B (th) อนุพันธ์ 4,5-ไดไฮโดร-ออกซาซอล-2-อิล
TH133917A (th) อนุพันธ์เฮทเทอโรไซคลิก เอมีน (Heterocyclic amine)
TH106465A (th) โดพามีน 2 รีเซพเทอร์แอนทาโกนิสท์ที่แยกออกได้เร็ว

Legal Events

Date Code Title Description
FB Suspension of granting procedure